Friday, 19th April 2024
To guardian.ng
Search

NAFDAC licenses ABUAD to produce COVID -19 herbal drug

By Ayodele Afolabi, Ado-Ekiti
20 December 2021   |   3:10 am
The National Agency for Food and Drug Administration and Control (NAFDAC) has given approval to Afe Babalola University Ado-Ekiti (ABUAD) to commence the production of ABUAD

Afe Babalola University (ABUAD)

The National Agency for Food and Drug Administration and Control (NAFDAC) has given approval to Afe Babalola University Ado-Ekiti (ABUAD) to commence the production of ABUAD Herbal Virucidine Liquid with effect from December 16, 2021.

ABUAD Herbal Virucidine Liquid is an immune booster and antioxidant for coronavirus and other viral infections, which can also be used as an anti-inflammatory agent. It is a product, which has been conscientiously produced and packaged in 100-ml bottles.

According to a statement by the Director, Corporate Affairs of the university, Mr. Tunde Olofintila, yesterday, with this achievement, ABUAD has joined researchers in some foreign universities, which have been making efforts to produce anti-viral medications for the treatment of COVID-19.

Olofintila said that the approval was conveyed in a letter dated December 17, 2021, and signed by the Director-General of NAFDAC, Prof. Mojisola C. Adeyeye.

In his comment on the development, Founder & Chancellor of the university, Aare Afe Babalola (SAN), recalled that the university was founded on three pillars of quality and functional education, research and community service in order to reform education and revive research in Nigerian Universities.

Also, the university’s Director of Research, Prof. Opemiposi Omotuyi, pointed out that the research breakthrough on herbal medicine had been made possible by the unparalleled assemblage of quality and sophisticated equipment and infrastructure in the university.

The university’s Chief Pharmacist, Mrs. Toyin Afolabi, expressed gratitude to stakeholders like the National Universities Commission (NUC), the Medical & Dental Council of Nigeria (MDCN), parents, committed and dedicated teachers and students who made the university what it is today.

Meanwhile, the Chief Medical Director of ABUAD Multi-System Hospital, Dr. Kolawole Ogundipe, appealed to industries in Nigeria to reach out to and partner with ABUAD in research and investment in products and services to enhance the quality of their products and quality of life of humanity.

Ogundipe, who advised prospective marketers of the liquid to start filing their applications, appealed to them to be patient until the herbal factory located in the university’s 121-unit Research Industrial Park would be completed in February 2022.”

0 Comments